WO2013162350A3 - Circular antiviral rna - Google Patents

Circular antiviral rna Download PDF

Info

Publication number
WO2013162350A3
WO2013162350A3 PCT/MY2013/000088 MY2013000088W WO2013162350A3 WO 2013162350 A3 WO2013162350 A3 WO 2013162350A3 MY 2013000088 W MY2013000088 W MY 2013000088W WO 2013162350 A3 WO2013162350 A3 WO 2013162350A3
Authority
WO
WIPO (PCT)
Prior art keywords
tfo
circular
treatment
relates
present
Prior art date
Application number
PCT/MY2013/000088
Other languages
French (fr)
Other versions
WO2013162350A2 (en
Inventor
Abdul Rahman Omar
Bimo A. TEJO
Sheau Wei TAN
Oi Kuan CHOONG
Original Assignee
Universiti Putra Malaysia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiti Putra Malaysia filed Critical Universiti Putra Malaysia
Publication of WO2013162350A2 publication Critical patent/WO2013162350A2/en
Publication of WO2013162350A3 publication Critical patent/WO2013162350A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/152—Nucleic acids forming more than 2 strands, e.g. TFOs on a single-stranded target, e.g. fold-back TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to triple helix forming oligonucleotides (TFO) for use in the treatment of diseases mediated by single stranded RNA viruses, for example corona viruses. The invention provides a selection of circular TFO sequences that target different regions of the genome of the virulent Feline coronavirus and that efficiently block the virus' replication. Thereby the TFO of the present invention provide new means for therapy against viral diseases. The invention relates to the novel TFOs, pharmaceutical compositions comprising the same, the new TFO design and their uses in the treatment of viral diseases.
PCT/MY2013/000088 2012-04-25 2013-04-23 Circular antiviral rna WO2013162350A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MYPI2012001820 2012-04-25
MYPI2012001820 2012-04-25

Publications (2)

Publication Number Publication Date
WO2013162350A2 WO2013162350A2 (en) 2013-10-31
WO2013162350A3 true WO2013162350A3 (en) 2013-12-19

Family

ID=49483998

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MY2013/000088 WO2013162350A2 (en) 2012-04-25 2013-04-23 Circular antiviral rna

Country Status (1)

Country Link
WO (1) WO2013162350A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017065405A1 (en) * 2015-10-15 2017-04-20 한국과학기술원 Antiviral agent comprising rna oligonucleotide
KR101842679B1 (en) 2015-10-15 2018-03-28 한국과학기술원 Rna oligonucleotide and enhancer of immune system comprising the same
EP3929295A1 (en) 2020-06-26 2021-12-29 Universitat Pompeu Fabra Artificial rnas for modulating rna fragments

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148985A1 (en) * 2001-12-05 2003-08-07 David Morrissey Methods and reagents for the inhibition of hepatitis B virus replication

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148985A1 (en) * 2001-12-05 2003-08-07 David Morrissey Methods and reagents for the inhibition of hepatitis B virus replication

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KNAUERT, MELISSA P. ET AL.: "Triplex forming oligonucleotides: sequence- specific tools for gene targeting", HUMAN MOLECULAR GENETICS, vol. 10, no. 20, 2001, pages 2243 - 2251 *
MACRIS, MARGARET A. ET AL.: "Transcription dependence of chromosome gene targeting by triplex-forming oligonucleotides", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 5, 31 January 2003 (2003-01-31), pages 3357 - 3362 *
SIMON, PHILIPPE ET AL.: "Targeting DNA with triplex-forming oligonucleotides to modify gene sequence", BIOCHIMIE, vol. 90, no. ISSUE, 2008, pages 1109 - 1116 *
YE, ZHAOYANG ET AL.: "Sequence-specific triple helix formation with genomic DNA", BIOCHEMISTRY, vol. 46, no. 40, 11 September 2007 (2007-09-11), pages 11240 - 11252 *

Also Published As

Publication number Publication date
WO2013162350A2 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
WO2013074974A3 (en) Modified rnai agents
MX2013009191A (en) Antisense oligonucleotides.
MX2017002144A (en) Modified double-stranded rna agents.
WO2017070626A3 (en) Respiratory virus vaccines
WO2015138357A3 (en) Compositions useful in treatment of otc deficency
WO2013016352A8 (en) Recombinant virus products and methods for inhibition of expression of dux4
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
WO2007053696A3 (en) Rnai inhibition of influenza virus replication
WO2016061232A3 (en) Multiplexed shrnas and uses thereof
MY166557A (en) Quinazoline derivatives for the treatment of viral infections and further diseases
MX355267B (en) 2'- substituted carba-nucleoside analogs for antiviral treatment.
EA025278B9 (en) Antiviral composition against dna or rna enveloped or non-enveloped viruses
BR112017005111A2 (en) compounds, pharmaceutical composition, uses of a compound or a pharmaceutically acceptable salt thereof for the treatment of a host infected with a human papillomavirus, uses of a compound, method for the manufacture of a medicament for therapeutic use in the treatment of a papillomavirus infection
EA201490654A1 (en) NEW INHIBITORS OF VIRAL REPLICATION
EA202090994A1 (en) COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF HEPATITIS B VIRUS GENES
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2015168108A3 (en) Methods for treating cancer using nucleic targeting mdm2 or mycn
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
EP3512863A4 (en) 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
WO2012030626A3 (en) Design of oligonucleotide analogs as therapeutic agents
MY201105A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
RU2015129287A (en) Apoptosis-inducing agent
WO2014066915A3 (en) Methods and compositions to produce ss-rnai activity with enhanced potency
WO2019217397A3 (en) Compositions and methods for improving strand biased
BR112013027098A2 (en) recombinant virus products and methods for inhibiting myotylin expression

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13782115

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, FORM 1205A DATED 13-02-2015

122 Ep: pct application non-entry in european phase

Ref document number: 13782115

Country of ref document: EP

Kind code of ref document: A2